Biocon Biologicals’ IPO only after integrating Viatris: CEO
1 year, 4 months ago

Biocon Biologicals’ IPO only after integrating Viatris: CEO

Live Mint  

MUMBAI : Biocon Biologics Ltd, the biosimilar arm of Biocon, will consider a listing only after it completes the integration of its Viatris portfolio, which is due by the end of March, the company’s chief executive officer Shreehas Tambe said in an interview. Biocon Biologics had acquired Viatris’ global biosimilar portfolio for $3.34 billion in November 2022 in a cash and equity transaction. Biocon Biologics has accelerated the process of integration, and is looking to integrate the Viatris portfolio within a year compared to the earlier guidance of two years, he said. Tambe said the company could post nearly 100% revenue growth due to the Viatris business and had also been able to generate robust growth for its core businesses of oncology and diabetes, across advanced and emerging markets.

Company Tambe Biocon Biocon Biologics Biosimilar Bevacizumab Viatris Ceo  tambe  biocon  biosimilar  biologicals  looking  crore  viatris  ceo  company  integrating  ipo  business  integration  biologics

History of this topic

Biocon share price in focus after arm launches product in US for autoimmune diseases
1 month, 1 week ago

Biocon share price in focus after arm launches product in US for autoimmune diseases

Live Mint  

Biocon share price rose by 2.5% during Tuesday's trading session following the launch of a biosimilar product by its subsidiary, Biocon Biologics, aimed at treating specific autoimmune disorders in the US market. This represents one of the initial biosimilar launches for Stelara, enhancing affordable treatment alternatives for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Biocon share price today …

Upcoming IPO: Biocon plans to list biosimilars business on stock exchanges by March 2026
2 months ago

Upcoming IPO: Biocon plans to list biosimilars business on stock exchanges by March 2026

Live Mint  

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches, a top executive told Reuters on Friday. The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring …

Biocon Biologics sees insulin demand growing across markets, says CEO Tambe
2 months ago

Biocon Biologics sees insulin demand growing across markets, says CEO Tambe

Live Mint  

Biocon Biologics Ltd expects a significant rise in demand for its insulin products across geographies in the coming months and years, managing director and chief executive Shreehas Tambe said on Friday. Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in …

Biocon shares surge over 7% after HSBC upgraded stock to ‘buy’, raised target price
2 months, 2 weeks ago

Biocon shares surge over 7% after HSBC upgraded stock to ‘buy’, raised target price

Live Mint  

Shares of Biocon saw a significant surge of over 7 percent on Tuesday, January 14, 2025, following an upgrade by global brokerage firm HSBC. The firm raised its rating on the stock to ‘Buy’ and set a new price target of ₹430 per share, up from ₹290 previously. HSBC highlighted several factors that could drive earnings growth, including the FDA’s …

Explained: Why Biocon share price climbed over 4% in early trade today
Trending News
2 months, 2 weeks ago

Explained: Why Biocon share price climbed over 4% in early trade today

India Today  

Shares of Biocon surged over 4% in early trade on Monday, following positive developments at its subsidiary Biocon Biologics’ Johor Bahru facility in Malaysia. Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange. The inspection included several biologics manufacturing units, including a Drug Substance unit, a Drug Product …

Explained: Why Biocon share price jumped over 7% today
2 months, 3 weeks ago

Explained: Why Biocon share price jumped over 7% today

India Today  

Shares of Biocon surged over 7% in early trade on January 7, following an upgrade from international brokerage Jefferies. The firm raised its rating on Biocon to 'underperform' and increased its target price by 43% to Rs 400, citing positive developments around the regulatory approval of the company’s manufacturing facility in Bengaluru. BIG FDA BOOST The key trigger for the …

Biocon Biologics to sell India branded formulations biz to Eris Lifesciences for ₹1,242 cr
1 year ago

Biocon Biologics to sell India branded formulations biz to Eris Lifesciences for ₹1,242 cr

Live Mint  

Branded formulations company Eris Lifesciences Ltd will acquire the domestic branded formulation business of Biocon Biologics Ltd, the biosimilar arm of Biocon, for ₹1,242 crore, the two companies said on Thursday. “This strategic collaboration with Eris Lifesciences for our portfolio of metabolics, oncology, and critical care products in India aligns with our commercial strategy to maximize patient reach and market …

Biocon Biologics integrates Vitaris’ biosimilars business
1 year, 3 months ago

Biocon Biologics integrates Vitaris’ biosimilars business

Live Mint  

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, on Monday announced a complete integration of the acquired Vitaris’ biosimilars business in 120 countries, a year ahead of schedule. With the completion of this significant milestone, Biocon Biologics is now a unique, fully-integrated ‘lab to market’ biosimilars company,” the company said in a statement. “Biocon Biologics will now have a strong …

‘Biocon Biologics ahead of plan in integrating Viatris’
1 year, 8 months ago

‘Biocon Biologics ahead of plan in integrating Viatris’

Live Mint  

MUMBAI : Biocon Biologics Ltd, the biosimilar unit of drugmaker Biocon Ltd, has achieved a third of its post-deal integration with Viatris’s global biosimilar portfolio ahead of time and expects to focus on integrating its US and European operations in the next phase, chief executive Shreehas Tambe said, adding the company also expects to raise additional capital this year. On …

Serum Institute to double investment in Biocon’s unit to $300 million
1 year, 11 months ago

Serum Institute to double investment in Biocon’s unit to $300 million

Live Mint  

As part of its expansion of investment in one of Biocon Ltd's units, Serum Institute of Life Sciences will give it access to 100 million vaccine doses annually. As per the new alliance, the company would pump in $150 million after converting a loan to Biocon Pharma Limited into equity in Biocon Biologics Ltd. The investment made is in addition …

Saraf And Partners Acts For Viatris In Its Sale Of Biosimilars Business To Biocon Biologics For US$ 3.335 Billion
2 years, 4 months ago

Saraf And Partners Acts For Viatris In Its Sale Of Biosimilars Business To Biocon Biologics For US$ 3.335 Billion

Live Law  

Global healthcare company - Viatris has, on November 29, completed the sale of its global biosimilars business to Biocon Biologics Limited, subsidiary of Biocon Limited for USD 3.335 billion for stock and cash consideration. The sale of global biosimilars business marks monumental moment to develop a future direction for Viatris that will not only unlock immediate value but will also …

M&A deal value in healthcare, pharma hits record high in first half of 2022
2 years, 8 months ago

M&A deal value in healthcare, pharma hits record high in first half of 2022

Live Mint  

India’s healthcare and pharmaceutical sector saw hectic deal activity with the value of merger and acquisitions in the first six months of this calendar year scaling a record high and crossing the total deal value of $3.35 billion in 2021. M&A deal value in the sector touched $4.32 billion during January to June, compared to $2.02 billion in the same …

Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw
3 years, 1 month ago

Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw

Live Mint  

Biocon's subsidiary Biocon Biologics will file for an initial public offer within next two years, Executive Chairperson Kiran Mazumdar-Shaw on Monday informed. Biocon Biologics, which has inked a deal to acquire Viatris Inc's biosimilars business for up to ₹24,990 crore, aims to be a fully integrated global biosimilars firm. This acquisition of Viatris' biosimilar business is an important step to …

Biocon arm to acquire biosimilars business of Viatris for $3.34 bn
3 years, 1 month ago

Biocon arm to acquire biosimilars business of Viatris for $3.34 bn

The Hindu  

Biocon subsidiary Biocon Biologics Ltd has entered into a definitive agreement with its partner Viatris Inc to acquire Viatris’ biosimilars business for $3.34 billion. Kiran Mazumdar Shaw, executive chairperson of Biocon Biologics on Monday said BBL has entered into an agreement with Viatris to acquire its biosimilars business for $3.34 billion, which would include cash of up to $2.34 billion …

Biocon Q3 net profit falls 19% to ₹186.6 cr
4 years, 2 months ago

Biocon Q3 net profit falls 19% to ₹186.6 cr

Hindustan Times  

Biotechnology major Biocon has reported an 18.97 per cent fall in consolidated profit at ₹186.6 crore for the quarter ended December 31, 2020 on account of higher expenses. The company's revenue from operations rose to ₹ 1,851 crore for the quarter under consideration, up 7.81 per cent, as against ₹ 1,716.8 crore during the same period a year ago The …

Biocon sees approvals unlocking $1 billion biosimilar sales
7 years ago

Biocon sees approvals unlocking $1 billion biosimilar sales

Live Mint  

Mumbai: Biocon Ltd, the only Indian drugmaker to win approval to sell copies of a biologic drug in the US, expects its business in that nascent sector will generate $1 billion in revenue by 2025 as it clears further regulatory hurdles this year. The company’s other leading drug candidates are back on track for approval after hiccups in the US …

Biocon profit down 46% to Rs91.9 crore in December quarter
7 years, 2 months ago

Biocon profit down 46% to Rs91.9 crore in December quarter

Live Mint  

Mumbai: Biocon Ltd’s consolidated net profit declined 46% to Rs91.9 crore in the quarter ended 31 December as interest and depreciation costs relating to its Malaysia facility rose. The Bengaluru-based company’s net sales rose 1.3% to Rs1,057.9 crore during the quarter from a year earlier. Segment-wise, Biocon’s branded formulations business, which includes sales in India and the UAE, reported revenue …

Biotech company, Biocon reports 52 percent annual growth
8 years, 5 months ago

Biotech company, Biocon reports 52 percent annual growth

Firstpost  

Biotech major Biocon Ltd on Thursday reported Rs 147 crore consolidated net profit for second quarter of fiscal 2016-17, registering 57 per cent annual growth from Rs 97 crore in same period year ago. Biotech major Biocon Ltd on Thursday reported Rs 147 crore consolidated net profit for second quarter of fiscal 2016-17, registering 57 percent annual growth from Rs …

Biocon net profit climbs 17 per cent
8 years, 8 months ago

Biocon net profit climbs 17 per cent

The Hindu  

Biocon Ltd., India’s biggest biotech company, reported a 17 per cent increase in first-quarter profit, helped by healthy demand for its biosimilar drugs. The Bengaluru-based firm said the consolidated total revenue increased by 11 per cent year-on-year to Rs.952 crore for the first quarter from Rs.857 crore. “Our strong performance this quarter has been driven by an all-round growth of …

Biocon files IPO prospectus for R&D arm Syngene to raise Rs 600 cr
9 years, 11 months ago

Biocon files IPO prospectus for R&D arm Syngene to raise Rs 600 cr

Firstpost  

The company plans to sell 22 million equity shares, including reservation of up to two million shares for Biocon shareholders, through an offer for sale. New Delhi: Biotechnology major Biocon today filed prospectus with market regulator SEBI for the initial public offer of its research arm Syngene through which aims to raise around Rs 600 crore that will be used …

Biocon Q4 net dips 54% at Rs 113 crore
10 years, 11 months ago

Biocon Q4 net dips 54% at Rs 113 crore

India TV News  

Biocon Q4 net dips 54% at Rs 113 crore New Delhi: Biotechnology major Biocon today reported a 54.51% decline in its consolidated net profit at Rs 113.08 crore for the fourth quarter ended March 31, 2014. The company had posted a net profit of New Delhi: Biotechnology major Biocon today reported a 54.51% decline in its consolidated net profit at …

Biocon reports Q3 net profit of Rs 105 cr, up 14%
11 years, 2 months ago

Biocon reports Q3 net profit of Rs 105 cr, up 14%

Firstpost  

The key highlight was the DCGI approval for our biosimilar Trastuzumab, which paved the way for its commercial launch in India as CANMAb. New Delhi: Bangalore-based biotech major Biocon Ltd today reported 14.41 percent increase in its consolidated net profit for the third quarter ended December 31, 2013 at Rs 104.99 crore. Commenting on the quarterly performance, Biocon Chairman and …

Discover Related